BPL-003

Phase 2Small molecule

BBeckley Psytech Limited

BPL-003 is one of 29 small molecule programs targeting Treatment Resistant Depression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Treatment Resistant DepressionRecruiting

Treatment Resistant DepressionPhase 2

Recruiting

Competition

Competitive Landscape

32 competitors in Treatment Resistant Depression

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

24 2

Spravato

WWim Janssens

Approved

15 3

Risperdal

WWim Janssens

Approved

5 4

Lithobid

SSolvay Pharmaceuticals

Approved

4 5

Bayer Aspirin

Bayer

Approved

—6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

3 7

Abilify

Otsuka

Approved

3 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

2 9

Mirapex

Boehringer Ingelheim

Approved

2 10

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Treatment Resistant Depression

NCT05660642

Clinical

Trials by Indication[1]

Treatment Resistant Depression2 trials

A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, With Open Label Extension, in Patients With Treatment-Resistant Depression

Completed·BBeckley Psytech Limited·Phase 2·NCT05870540·196 enrolled

An Open-Label, Phase 2a Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

Recruiting·BBeckley Psytech Limited·Phase 2·NCT05660642·72 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study With BPL-003 in Healthy Subjects

Completed·BBeckley Psytech Limited·Phase 1·NCT05347849·62 enrolled

Alcohol Use Disorder1 trial

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

Completed·BBeckley Psytech Limited·Phase 2·NCT05674929·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BPL-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BPL-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BPL-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beckley Psytech Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeckley Psytech Limited

BPL-003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Treatment Resistant Depression2 trials

Single Ascending Dose1 trial

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News